Annual Activities Report 2011 - INCT-Inofar - UFRJ
Annual Activities Report 2011 - INCT-Inofar - UFRJ
Annual Activities Report 2011 - INCT-Inofar - UFRJ
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Annual</strong> <strong>Report</strong> <strong>2011</strong> | <strong>INCT</strong>-INOFAR<br />
9<br />
Editorial<br />
contribution to the full verticalization of the chain of generic medications, representing a synthesis<br />
technology capable of being scaled and transferred to the business sector, public or otherwise, in case the<br />
Ministry of Health decides to support it. We understand that the synthesis of this important anticancer<br />
drug supports, in a significant manner, a future political decision by the Brazilian government on the issue.<br />
The second drug, fluoxetine, which does not have an effective patent, represents another contribution by<br />
the research group to led by Professor Dias (UNICAMP) to our technological qualification in generic<br />
drugs, because it is an important resource in the treatment of central illnesses. Still in the environment of<br />
incremental innovation, we also achieved, in <strong>2011</strong>, a patent request for the synthesis route developed by<br />
the same group for atorvastatin (see page 55), described in our AAR-2010. Considering that atorvastatin<br />
is the most valuable drug in the market, a member of the HMGCoA-reductase inhibitors, which made<br />
Pfizer worldwide, during the patent monopoly (1991-2001), a total of US$ 120 billion. Considering<br />
this is the biggest best seller in the history of drugs, and that its patent was voided in November <strong>2011</strong> in<br />
its main world market and a few months before that in Brazil, it then became the most promising and<br />
coveted generic drug, since the branded drug (Lipitor TM ), sold, worldwide, US$ 13 billion just on the<br />
last year the patent was effective. The synthetic route developed by <strong>INCT</strong>-INOFAR greatly surpasses the<br />
efficiency and yield of the original one described by Pfizer, so this patent request represents an important<br />
technological property created by <strong>INCT</strong>-INOFAR, deserving future scaling and transfer to the drug<br />
industry sector.<br />
There were countless activities carried out by <strong>INCT</strong>-INOFAR during this time referring to education,<br />
promotion, and increasing awareness of pharmaceutical sciences, and they are listed in a bilingual<br />
booklet, which is available in our portal (www.inct-inofar.ccs.ufrj.br/revista). We highlight the booklet<br />
on the correct and rational use of medications in general (http://www.portaldosfarmacos.ccs.ufrj.br/)<br />
and most of all, the second booklet, on antibiotics (http://www.portaldosfarmacos.ccs.ufrj.br/). This<br />
second booklet was made available at the site for the Brazilian regulatory agency (ANVISA), and it<br />
will have an animated version produced by <strong>INCT</strong>-INOFAR, currently under production. O <strong>INCT</strong>-<br />
INOFAR keeps the Pharmaceuticals Portal updated (http://www.portaldosfarmacos.ccs.ufrj.br), a web<br />
page where it publicizes its activities and publishes articles on topics related to drugs and medications<br />
(http://www.portaldosfarmacos.ccs.ufrj.br/).<br />
I wish that this volume of the <strong>Annual</strong> <strong>Activities</strong> <strong>Report</strong> of the National Institute of Science and<br />
Technology in Drugs and Medicines (<strong>INCT</strong>-INOFAR), describing the activities developed in <strong>2011</strong>, is a<br />
pleasant and easy read, as well as a perpetual reference source.<br />
Rio de Janeiro, June 2012.<br />
Eliezer J. Barreiro<br />
<strong>INCT</strong>-INOFAR Coordinator